!Sample_geo_accession,!Sample_status,!Sample_submission_date,!Sample_last_update_date,!Sample_type,!Sample_channel_count,!Sample_source_name_ch1,!Sample_organism_ch1,!Sample_characteristics_ch1,!Sample_characteristics_ch1,!Sample_characteristics_ch1,!Sample_characteristics_ch1,!Sample_characteristics_ch1,!Sample_characteristics_ch1,!Sample_molecule_ch1,!Sample_extract_protocol_ch1,!Sample_extract_protocol_ch1,!Sample_taxid_ch1,!Sample_description,!Sample_data_processing,!Sample_data_processing,!Sample_data_processing,!Sample_data_processing,!Sample_data_processing,!Sample_data_processing,!Sample_platform_id,!Sample_contact_name,!Sample_contact_email,!Sample_contact_laboratory,!Sample_contact_department,!Sample_contact_institute,!Sample_contact_address,!Sample_contact_city,!Sample_contact_zip/postal_code,!Sample_contact_country,!Sample_data_row_count,!Sample_instrument_model,!Sample_library_selection,!Sample_library_source,!Sample_library_strategy,!Sample_relation,!Sample_relation,!Sample_supplementary_file_1,!series_matrix_table_begin,"""ID_REF""",!series_matrix_table_end
"""GSM1662534""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""3-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-03""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495628""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001490""","""NONE""",,"""GSM1662534""",
"""GSM1662535""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""8-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-08""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495629""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001491""","""NONE""",,"""GSM1662535""",
"""GSM1662536""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""10-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-10""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495630""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001492""","""NONE""",,"""GSM1662536""",
"""GSM1662537""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-100""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-100""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495631""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001493""","""NONE""",,"""GSM1662537""",
"""GSM1662538""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""15-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-15""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495632""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001494""","""NONE""",,"""GSM1662538""",
"""GSM1662539""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""16-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-16""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495633""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001495""","""NONE""",,"""GSM1662539""",
"""GSM1662540""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""21-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-21""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495634""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001496""","""NONE""",,"""GSM1662540""",
"""GSM1662541""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""33-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-33""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495635""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001497""","""NONE""",,"""GSM1662541""",
"""GSM1662542""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""42-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-42""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+, PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495636""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001498""","""NONE""",,"""GSM1662542""",
"""GSM1662543""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-454""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-454""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495637""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001499""","""NONE""",,"""GSM1662543""",
"""GSM1662544""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""48-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-48""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495638""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001500""","""NONE""",,"""GSM1662544""",
"""GSM1662545""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""50-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-50""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495639""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001501""","""NONE""",,"""GSM1662545""",
"""GSM1662546""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""55-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-55""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495640""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001502""","""NONE""",,"""GSM1662546""",
"""GSM1662547""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Type-Unknown-6""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-56""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495641""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001503""","""NONE""",,"""GSM1662547""",
"""GSM1662548""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-564""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-564""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495642""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001504""","""NONE""",,"""GSM1662548""",
"""GSM1662549""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""59-Breast-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-59""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495643""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001505""","""NONE""",,"""GSM1662549""",
"""GSM1662550""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-590""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-590""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495644""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001506""","""NONE""",,"""GSM1662550""",
"""GSM1662551""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-60""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-60""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495645""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001507""","""NONE""",,"""GSM1662551""",
"""GSM1662552""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-603""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-603""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495646""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001508""","""NONE""",,"""GSM1662552""",
"""GSM1662553""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""ALK61-Breast-Her2-unknown""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-61""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495647""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001509""","""NONE""",,"""GSM1662553""",
"""GSM1662554""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-85""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-85""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: Triple Negative""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495648""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001510""","""NONE""",,"""GSM1662554""",
"""GSM1662555""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-86""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-86""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495649""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001511""","""NONE""",,"""GSM1662555""",
"""GSM1662556""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""97-Breast-Her2-ampl""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-97""","""cancer type: Breast""","""batch: Batch03""","""mutational subclass: HER2+, PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495650""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001512""","""NONE""",,"""GSM1662556""",
"""GSM1662557""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Breast-ALK-82""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Breast-ALK-82""","""cancer type: Breast""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495651""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001513""","""NONE""",,"""GSM1662557""",
"""GSM1662558""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""292-Liver-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-292""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495652""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001514""","""NONE""",,"""GSM1662558""",
"""GSM1662559""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""316-Liver-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-316""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495653""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001515""","""NONE""",,"""GSM1662559""",
"""GSM1662560""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""341-Liver-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-341""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495654""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001516""","""NONE""",,"""GSM1662560""",
"""GSM1662561""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""376-Liver-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-376""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495655""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001517""","""NONE""",,"""GSM1662561""",
"""GSM1662562""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""379-Liver-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-379""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495656""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001518""","""NONE""",,"""GSM1662562""",
"""GSM1662563""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Chol-410""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-410""","""cancer type: Hepatobiliary""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495657""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001519""","""NONE""",,"""GSM1662563""",
"""GSM1662564""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Chol-442""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-442""","""cancer type: Hepatobiliary""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495658""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001520""","""NONE""",,"""GSM1662564""",
"""GSM1662565""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Chol-460""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-460""","""cancer type: Hepatobiliary""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495659""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001521""","""NONE""",,"""GSM1662565""",
"""GSM1662566""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Chol-611""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-611""","""cancer type: Hepatobiliary""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495660""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001522""","""NONE""",,"""GSM1662566""",
"""GSM1662567""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Chol-ALK-28""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Chol-ALK-28""","""cancer type: Hepatobiliary""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495661""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001523""","""NONE""",,"""GSM1662567""",
"""GSM1662568""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU256-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-256""","""cancer type: CRC""","""batch: Batch02""","""mutational subclass: PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495700""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001524""","""NONE""",,"""GSM1662568""",
"""GSM1662569""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU258-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-258""","""cancer type: CRC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note this sample did not yield sufficient number of total mapped intron-spanning reads and was thus excluded from analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495701""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001525""","""NONE""",,"""GSM1662569""",
"""GSM1662570""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU272-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-272""","""cancer type: CRC""","""batch: Batch02""","""mutational subclass: PIK3CA""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495698""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001526""","""NONE""",,"""GSM1662570""",
"""GSM1662571""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU276-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-276""","""cancer type: CRC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495699""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001527""","""NONE""",,"""GSM1662571""",
"""GSM1662572""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Type-Unknown-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-304""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495702""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001528""","""NONE""",,"""GSM1662572""",
"""GSM1662573""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""329-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-329""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495703""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001529""","""NONE""",,"""GSM1662573""",
"""GSM1662574""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""342-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-342""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495704""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001530""","""NONE""",,"""GSM1662574""",
"""GSM1662575""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Type-Unknown-5""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-351""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495705""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001531""","""NONE""",,"""GSM1662575""",
"""GSM1662576""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""354-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-354""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495706""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001532""","""NONE""",,"""GSM1662576""",
"""GSM1662577""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""356-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-356""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495707""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001533""","""NONE""",,"""GSM1662577""",
"""GSM1662578""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-357""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-357""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495708""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001534""","""NONE""",,"""GSM1662578""",
"""GSM1662579""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""374-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-374""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495709""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001535""","""NONE""",,"""GSM1662579""",
"""GSM1662580""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""378-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-378""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495715""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001536""","""NONE""",,"""GSM1662580""",
"""GSM1662581""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""420-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-420""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495716""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001537""","""NONE""",,"""GSM1662581""",
"""GSM1662582""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""429-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-429""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495711""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001538""","""NONE""",,"""GSM1662582""",
"""GSM1662583""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-450""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-450""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495712""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001539""","""NONE""",,"""GSM1662583""",
"""GSM1662584""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""453-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-453""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495713""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001540""","""NONE""",,"""GSM1662584""",
"""GSM1662585""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-459""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-459""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495714""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001541""","""NONE""",,"""GSM1662585""",
"""GSM1662586""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""462-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-462""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495710""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001542""","""NONE""",,"""GSM1662586""",
"""GSM1662587""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-463""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-463""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495717""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001543""","""NONE""",,"""GSM1662587""",
"""GSM1662588""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""466-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-466""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495718""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001544""","""NONE""",,"""GSM1662588""",
"""GSM1662589""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""474-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-474""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495719""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001545""","""NONE""",,"""GSM1662589""",
"""GSM1662590""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-487""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-487""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495720""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001546""","""NONE""",,"""GSM1662590""",
"""GSM1662591""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-496""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-496""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495721""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001547""","""NONE""",,"""GSM1662591""",
"""GSM1662592""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""497-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-497""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495722""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001548""","""NONE""",,"""GSM1662592""",
"""GSM1662593""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""504-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-504""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495723""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001549""","""NONE""",,"""GSM1662593""",
"""GSM1662594""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-511""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-511""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495724""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001550""","""NONE""",,"""GSM1662594""",
"""GSM1662595""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-523""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-523""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495725""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001551""","""NONE""",,"""GSM1662595""",
"""GSM1662596""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-524""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-524""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495726""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001552""","""NONE""",,"""GSM1662596""",
"""GSM1662597""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""527-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-527""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495729""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001553""","""NONE""",,"""GSM1662597""",
"""GSM1662598""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-531""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-531""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495662""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001554""","""NONE""",,"""GSM1662598""",
"""GSM1662599""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""543-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-543""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495663""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001555""","""NONE""",,"""GSM1662599""",
"""GSM1662600""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""546-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-546""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495664""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001556""","""NONE""",,"""GSM1662600""",
"""GSM1662601""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""548-CRC-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-548""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495665""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001557""","""NONE""",,"""GSM1662601""",
"""GSM1662602""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-552""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-552""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495666""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001558""","""NONE""",,"""GSM1662602""",
"""GSM1662603""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""556-CRC-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-556""","""cancer type: CRC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495667""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001559""","""NONE""",,"""GSM1662603""",
"""GSM1662604""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-565""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-565""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495427""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001560""","""NONE""",,"""GSM1662604""",
"""GSM1662605""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""CRC-576""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: CRC-576""","""cancer type: CRC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495428""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001561""","""NONE""",,"""GSM1662605""",
"""GSM1662606""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU280-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-280""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495429""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001562""","""NONE""",,"""GSM1662606""",
"""GSM1662607""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU284-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-284""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495430""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001563""","""NONE""",,"""GSM1662607""",
"""GSM1662608""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU306-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-306""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495431""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001564""","""NONE""",,"""GSM1662608""",
"""GSM1662609""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU360-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-360""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495432""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001565""","""NONE""",,"""GSM1662609""",
"""GSM1662610""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU372-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-372""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495433""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001566""","""NONE""",,"""GSM1662610""",
"""GSM1662611""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU378-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-378""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495434""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001567""","""NONE""",,"""GSM1662611""",
"""GSM1662612""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU383Platelet-hiseq""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-383""","""cancer type: GBM""","""batch: Batch01""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495435""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001568""","""NONE""",,"""GSM1662612""",
"""GSM1662613""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU393-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-393""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495436""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001569""","""NONE""",,"""GSM1662613""",
"""GSM1662614""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU394Platelet-hiseq""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-394""","""cancer type: GBM""","""batch: Batch01""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495437""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001570""","""NONE""",,"""GSM1662614""",
"""GSM1662615""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU398-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-398""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note this sample did not yield sufficient number of total mapped intron-spanning reads and was thus excluded from analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495438""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001571""","""NONE""",,"""GSM1662615""",
"""GSM1662616""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU402-2-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-402""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495439""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001572""","""NONE""",,"""GSM1662616""",
"""GSM1662617""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU406-2-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-406""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495440""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001573""","""NONE""",,"""GSM1662617""",
"""GSM1662618""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU408-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-408""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495441""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001574""","""NONE""",,"""GSM1662618""",
"""GSM1662619""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU417-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-417""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495442""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001575""","""NONE""",,"""GSM1662619""",
"""GSM1662620""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU418-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-418""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495443""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001576""","""NONE""",,"""GSM1662620""",
"""GSM1662621""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU419-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-419""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495444""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001577""","""NONE""",,"""GSM1662621""",
"""GSM1662622""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU421-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-421""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495445""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001578""","""NONE""",,"""GSM1662622""",
"""GSM1662623""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU422-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-422""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495446""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001579""","""NONE""",,"""GSM1662623""",
"""GSM1662624""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU425-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-425""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495447""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001580""","""NONE""",,"""GSM1662624""",
"""GSM1662625""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU429-1-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-429""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495448""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001581""","""NONE""",,"""GSM1662625""",
"""GSM1662626""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU430-GBM""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-430""","""cancer type: GBM""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495449""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001582""","""NONE""",,"""GSM1662626""",
"""GSM1662627""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU431-1-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-431""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495450""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001583""","""NONE""",,"""GSM1662627""",
"""GSM1662628""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU436-1-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-436""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495451""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001584""","""NONE""",,"""GSM1662628""",
"""GSM1662629""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-438""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-438""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495452""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001585""","""NONE""",,"""GSM1662629""",
"""GSM1662630""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU439-1-GBM-vIII""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-439""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495453""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001586""","""NONE""",,"""GSM1662630""",
"""GSM1662631""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-440""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-440""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495454""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001587""","""NONE""",,"""GSM1662631""",
"""GSM1662632""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU443-1-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-443""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495455""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001588""","""NONE""",,"""GSM1662632""",
"""GSM1662633""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU445-1-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-445""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495456""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001589""","""NONE""",,"""GSM1662633""",
"""GSM1662634""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU454-1-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-454""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495512""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001590""","""NONE""",,"""GSM1662634""",
"""GSM1662635""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU456-1-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-456""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495513""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001591""","""NONE""",,"""GSM1662635""",
"""GSM1662636""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU468-1-GBM-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-468""","""cancer type: GBM""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495514""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001592""","""NONE""",,"""GSM1662636""",
"""GSM1662637""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-471""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-471""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495515""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001593""","""NONE""",,"""GSM1662637""",
"""GSM1662638""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-475""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-475""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495516""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001594""","""NONE""",,"""GSM1662638""",
"""GSM1662639""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-476""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-476""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495517""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001595""","""NONE""",,"""GSM1662639""",
"""GSM1662640""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-480""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-480""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495518""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001596""","""NONE""",,"""GSM1662640""",
"""GSM1662641""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-484""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-484""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495519""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001597""","""NONE""",,"""GSM1662641""",
"""GSM1662642""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-485""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-485""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495520""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001598""","""NONE""",,"""GSM1662642""",
"""GSM1662643""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-486""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-486""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495521""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001599""","""NONE""",,"""GSM1662643""",
"""GSM1662644""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-499""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-499""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495522""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001600""","""NONE""",,"""GSM1662644""",
"""GSM1662645""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""GBM-505""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: GBM-505""","""cancer type: GBM""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495529""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001601""","""NONE""",,"""GSM1662645""",
"""GSM1662646""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-01""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495523""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001602""","""NONE""",,"""GSM1662646""",
"""GSM1662647""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-2-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-02""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495524""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001603""","""NONE""",,"""GSM1662647""",
"""GSM1662648""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-3-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-03""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note that the mapped and counted intron-spanning reads from both files corresponding to this sample were merged in silico to yield sufficient mapped reads for further analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495525""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001604""","""NONE""",,"""GSM1662648""",
"""GSM1662649""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-4""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-04""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495526""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001605""","""NONE""",,"""GSM1662649""",
"""GSM1662650""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-5""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-05""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495527""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001606""","""NONE""",,"""GSM1662650""",
"""GSM1662651""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-7""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-06""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495528""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001607""","""NONE""",,"""GSM1662651""",
"""GSM1662652""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-8""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-07""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495530""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001608""","""NONE""",,"""GSM1662652""",
"""GSM1662653""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-9""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-08""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495531""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001609""","""NONE""",,"""GSM1662653""",
"""GSM1662654""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-10""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-09""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495532""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001610""","""NONE""",,"""GSM1662654""",
"""GSM1662655""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-11-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-10""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495533""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001611""","""NONE""",,"""GSM1662655""",
"""GSM1662656""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-13-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-11""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495534""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001612""","""NONE""",,"""GSM1662656""",
"""GSM1662657""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-14-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-12""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495535""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001613""","""NONE""",,"""GSM1662657""",
"""GSM1662658""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-15-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-13""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495536""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001614""","""NONE""",,"""GSM1662658""",
"""GSM1662659""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-16-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-14""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495537""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001615""","""NONE""",,"""GSM1662659""",
"""GSM1662660""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-20-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-15""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note that the mapped and counted intron-spanning reads from both files corresponding to this sample were merged in silico to yield sufficient mapped reads for further analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495538""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001616""","""NONE""",,"""GSM1662660""",
"""GSM1662661""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-22-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-16""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495539""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001617""","""NONE""",,"""GSM1662661""",
"""GSM1662662""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-34-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-17""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495540""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001618""","""NONE""",,"""GSM1662662""",
"""GSM1662663""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-39-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-18""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495541""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001619""","""NONE""",,"""GSM1662663""",
"""GSM1662664""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-40-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-19""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495397""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001620""","""NONE""",,"""GSM1662664""",
"""GSM1662665""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-45-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-20""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495398""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001621""","""NONE""",,"""GSM1662665""",
"""GSM1662666""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-46-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-21""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495399""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001622""","""NONE""",,"""GSM1662666""",
"""GSM1662667""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-22""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495400""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001623""","""NONE""",,"""GSM1662667""",
"""GSM1662668""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-3""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-23""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495401""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001624""","""NONE""",,"""GSM1662668""",
"""GSM1662669""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-4""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-24""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495402""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001625""","""NONE""",,"""GSM1662669""",
"""GSM1662670""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-5""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-25""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495403""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001626""","""NONE""",,"""GSM1662670""",
"""GSM1662671""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-6""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-26""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495404""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001627""","""NONE""",,"""GSM1662671""",
"""GSM1662672""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-8""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-27""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495405""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001628""","""NONE""",,"""GSM1662672""",
"""GSM1662673""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-9""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-28""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495406""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001629""","""NONE""",,"""GSM1662673""",
"""GSM1662674""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-10""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-29""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495407""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001630""","""NONE""",,"""GSM1662674""",
"""GSM1662675""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Control-13""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-30""","""cancer type: HC""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495408""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001631""","""NONE""",,"""GSM1662675""",
"""GSM1662676""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Type-Unknown-3""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-31""","""cancer type: HC""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495409""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001632""","""NONE""",,"""GSM1662676""",
"""GSM1662677""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-17-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-32""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495410""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001633""","""NONE""",,"""GSM1662677""",
"""GSM1662678""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-18-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-33""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495411""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001634""","""NONE""",,"""GSM1662678""",
"""GSM1662679""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-21-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-34""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495412""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001635""","""NONE""",,"""GSM1662679""",
"""GSM1662680""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-24-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-35""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note that the mapped and counted intron-spanning reads from both files corresponding to this sample were merged in silico to yield sufficient mapped reads for further analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495413""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001636""","""NONE""",,"""GSM1662680""",
"""GSM1662681""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-25-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-36""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495414""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001637""","""NONE""",,"""GSM1662681""",
"""GSM1662682""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-26-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-37""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495415""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001638""","""NONE""",,"""GSM1662682""",
"""GSM1662683""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-27-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-38""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495416""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001639""","""NONE""",,"""GSM1662683""",
"""GSM1662684""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-29-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-39""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495417""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001640""","""NONE""",,"""GSM1662684""",
"""GSM1662685""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-30-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-40""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495418""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001641""","""NONE""",,"""GSM1662685""",
"""GSM1662686""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-31""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-41""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495419""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001642""","""NONE""",,"""GSM1662686""",
"""GSM1662687""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-32-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-42""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495420""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001643""","""NONE""",,"""GSM1662687""",
"""GSM1662688""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-33-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-43""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495421""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001644""","""NONE""",,"""GSM1662688""",
"""GSM1662689""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-35-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-44""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495422""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001645""","""NONE""",,"""GSM1662689""",
"""GSM1662690""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-36""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-45""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note that the mapped and counted intron-spanning reads from both files corresponding to this sample were merged in silico to yield sufficient mapped reads for further analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495423""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001646""","""NONE""",,"""GSM1662690""",
"""GSM1662691""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-37-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-46""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495424""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001647""","""NONE""",,"""GSM1662691""",
"""GSM1662692""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-38-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-47""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495425""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001648""","""NONE""",,"""GSM1662692""",
"""GSM1662693""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-44-2""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-48""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495426""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001649""","""NONE""",,"""GSM1662693""",
"""GSM1662694""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-47-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-49""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495668""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001650""","""NONE""",,"""GSM1662694""",
"""GSM1662695""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-48-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-50""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495669""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001651""","""NONE""",,"""GSM1662695""",
"""GSM1662696""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-49-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-51""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495670""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001652""","""NONE""",,"""GSM1662696""",
"""GSM1662697""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-50-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-52""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495671""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001653""","""NONE""",,"""GSM1662697""",
"""GSM1662698""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-51-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-53""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""Please note that the mapped and counted intron-spanning reads from both files corresponding to this sample were merged in silico to yield sufficient mapped reads for further analyses.""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495672""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001654""","""NONE""",,"""GSM1662698""",
"""GSM1662699""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-53-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-54""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495673""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001655""","""NONE""",,"""GSM1662699""",
"""GSM1662700""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""HD-54-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: HC-55""","""cancer type: HC""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495674""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001656""","""NONE""",,"""GSM1662700""",
"""GSM1662701""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU274-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Liver-274""","""cancer type: Hepatobiliary""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495675""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001657""","""NONE""",,"""GSM1662701""",
"""GSM1662702""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""297-Liver-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Liver-297""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495676""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001658""","""NONE""",,"""GSM1662702""",
"""GSM1662703""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""366-Liver-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Liver-366""","""cancer type: Hepatobiliary""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495681""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001659""","""NONE""",,"""GSM1662703""",
"""GSM1662704""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0082""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0082""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495682""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001660""","""NONE""",,"""GSM1662704""",
"""GSM1662705""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0096""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0096""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495683""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001661""","""NONE""",,"""GSM1662705""",
"""GSM1662706""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0001""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-01""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495677""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001662""","""NONE""",,"""GSM1662706""",
"""GSM1662707""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0100""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0100""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495678""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001663""","""NONE""",,"""GSM1662707""",
"""GSM1662708""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0101""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0101""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495679""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001664""","""NONE""",,"""GSM1662708""",
"""GSM1662709""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0102""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0102""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495680""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001665""","""NONE""",,"""GSM1662709""",
"""GSM1662710""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0104""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0104""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495684""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001666""","""NONE""",,"""GSM1662710""",
"""GSM1662711""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0110""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0110""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495685""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001667""","""NONE""",,"""GSM1662711""",
"""GSM1662712""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0112""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0112""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495686""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001668""","""NONE""",,"""GSM1662712""",
"""GSM1662713""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0119""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-0119""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495687""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001669""","""NONE""",,"""GSM1662713""",
"""GSM1662714""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-004-EGFR""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-04""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495688""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001670""","""NONE""",,"""GSM1662714""",
"""GSM1662715""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-006""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-06""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: EGFR""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495689""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001671""","""NONE""",,"""GSM1662715""",
"""GSM1662716""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0007""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-07""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495690""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001672""","""NONE""",,"""GSM1662716""",
"""GSM1662717""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-008""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-08""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: EGFR""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495691""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001673""","""NONE""",,"""GSM1662717""",
"""GSM1662718""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0012""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-12""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495692""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001674""","""NONE""",,"""GSM1662718""",
"""GSM1662719""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0014J""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-14""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495693""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001675""","""NONE""",,"""GSM1662719""",
"""GSM1662720""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0015""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-15""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495694""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001676""","""NONE""",,"""GSM1662720""",
"""GSM1662721""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0016""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-16""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495695""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001677""","""NONE""",,"""GSM1662721""",
"""GSM1662722""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0017""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-17""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495696""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001678""","""NONE""",,"""GSM1662722""",
"""GSM1662723""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0020J""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-20""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495697""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001679""","""NONE""",,"""GSM1662723""",
"""GSM1662724""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0020J-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-20-1""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495482""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001680""","""NONE""",,"""GSM1662724""",
"""GSM1662725""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0024J-1""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-24-1""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495483""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001681""","""NONE""",,"""GSM1662725""",
"""GSM1662726""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0025J""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-25""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495484""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001682""","""NONE""",,"""GSM1662726""",
"""GSM1662727""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0026J""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-26""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495485""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001683""","""NONE""",,"""GSM1662727""",
"""GSM1662728""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU271-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-271""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495486""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001684""","""NONE""",,"""GSM1662728""",
"""GSM1662729""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0029J-1-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-29""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495487""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001685""","""NONE""",,"""GSM1662729""",
"""GSM1662730""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0030J-1-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-30""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495489""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001686""","""NONE""",,"""GSM1662730""",
"""GSM1662731""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0037""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-37""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495490""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001687""","""NONE""",,"""GSM1662731""",
"""GSM1662732""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0040""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-40""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495491""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001688""","""NONE""",,"""GSM1662732""",
"""GSM1662733""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0042""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-42""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495492""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001689""","""NONE""",,"""GSM1662733""",
"""GSM1662734""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0046""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-46""","""cancer type: Lung""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495493""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001690""","""NONE""",,"""GSM1662734""",
"""GSM1662735""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0058-EGFR""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-58""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495494""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001691""","""NONE""",,"""GSM1662735""",
"""GSM1662736""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0061-EGFR""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-61""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: EGFR, MET""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495488""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001692""","""NONE""",,"""GSM1662736""",
"""GSM1662737""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0062-EGFR""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-62""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: EGFR""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495495""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001693""","""NONE""",,"""GSM1662737""",
"""GSM1662738""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-0074-EGFR""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-74""","""cancer type: Lung""","""batch: Batch03""","""mutational subclass: EGFR""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495496""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001694""","""NONE""",,"""GSM1662738""",
"""GSM1662739""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-L-13""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-L.13""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495497""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001695""","""NONE""",,"""GSM1662739""",
"""GSM1662740""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-L-15""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-L.15""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495498""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001696""","""NONE""",,"""GSM1662740""",
"""GSM1662741""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-L-26""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-L.26""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495499""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001697""","""NONE""",,"""GSM1662741""",
"""GSM1662742""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-L-33""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-L.33""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495500""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001698""","""NONE""",,"""GSM1662742""",
"""GSM1662743""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Lung-L-4""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Lung-L.4""","""cancer type: Lung""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495501""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001699""","""NONE""",,"""GSM1662743""",
"""GSM1662744""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""VU260-CRC""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-260""","""cancer type: Pancreas""","""batch: Batch02""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495502""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001700""","""NONE""",,"""GSM1662744""",
"""GSM1662745""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""286-Pancr-286-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-286""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495503""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001701""","""NONE""",,"""GSM1662745""",
"""GSM1662746""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""314-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-314""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495504""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001702""","""NONE""",,"""GSM1662746""",
"""GSM1662747""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""327-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-327""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495505""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001703""","""NONE""",,"""GSM1662747""",
"""GSM1662748""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""328-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-328""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495506""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001704""","""NONE""",,"""GSM1662748""",
"""GSM1662749""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""331-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-331""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495507""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001705""","""NONE""",,"""GSM1662749""",
"""GSM1662750""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-335""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-335""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495508""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001706""","""NONE""",,"""GSM1662750""",
"""GSM1662751""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""367-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-367""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495509""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001707""","""NONE""",,"""GSM1662751""",
"""GSM1662752""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""369-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-369""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495510""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001708""","""NONE""",,"""GSM1662752""",
"""GSM1662753""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-370""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-370""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495511""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001709""","""NONE""",,"""GSM1662753""",
"""GSM1662754""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""371-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-371""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495457""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001710""","""NONE""",,"""GSM1662754""",
"""GSM1662755""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""380-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-380""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495458""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001711""","""NONE""",,"""GSM1662755""",
"""GSM1662756""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""382-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-382""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495459""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001712""","""NONE""",,"""GSM1662756""",
"""GSM1662757""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""387-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-387""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495460""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001713""","""NONE""",,"""GSM1662757""",
"""GSM1662758""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""388-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-388""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495461""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001714""","""NONE""",,"""GSM1662758""",
"""GSM1662759""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""389-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-389""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495462""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001715""","""NONE""",,"""GSM1662759""",
"""GSM1662760""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""390-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-390""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495463""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001716""","""NONE""",,"""GSM1662760""",
"""GSM1662761""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""391-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-391""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495464""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001717""","""NONE""",,"""GSM1662761""",
"""GSM1662762""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""431-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-431""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495465""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001718""","""NONE""",,"""GSM1662762""",
"""GSM1662763""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""434-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-434""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495466""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001719""","""NONE""",,"""GSM1662763""",
"""GSM1662764""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-435""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-435""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495467""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001720""","""NONE""",,"""GSM1662764""",
"""GSM1662765""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""448-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-448""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495468""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001721""","""NONE""",,"""GSM1662765""",
"""GSM1662766""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Type-Unknown-4""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-449""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495469""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001722""","""NONE""",,"""GSM1662766""",
"""GSM1662767""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-451""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-451""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495470""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001723""","""NONE""",,"""GSM1662767""",
"""GSM1662768""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-461""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-461""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495471""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001724""","""NONE""",,"""GSM1662768""",
"""GSM1662769""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-477""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-477""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495472""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001725""","""NONE""",,"""GSM1662769""",
"""GSM1662770""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""488-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-488""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495473""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001726""","""NONE""",,"""GSM1662770""",
"""GSM1662771""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-493""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-493""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495474""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001727""","""NONE""",,"""GSM1662771""",
"""GSM1662772""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""498-Pancr-WT""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-498""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495475""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001728""","""NONE""",,"""GSM1662772""",
"""GSM1662773""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-501""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-501""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495476""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001729""","""NONE""",,"""GSM1662773""",
"""GSM1662774""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-503""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-503""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495477""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001730""","""NONE""",,"""GSM1662774""",
"""GSM1662775""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""512-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-512""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495478""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001731""","""NONE""",,"""GSM1662775""",
"""GSM1662776""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""553-Pancr-KRAS""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-553""","""cancer type: Pancreas""","""batch: Batch03""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495479""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001732""","""NONE""",,"""GSM1662776""",
"""GSM1662777""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-593""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-593""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: KRAS""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495480""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001733""","""NONE""",,"""GSM1662777""",
"""GSM1662778""","""Public on Oct 30 2015""","""Apr 21 2015""","""May 15 2019""","""SRA""","""1""","""Panc-597""","""Homo sapiens""","""tissue: blood""","""cell type: Thrombocytes""","""patient id: Panc-597""","""cancer type: Pancreas""","""batch: Batch04""","""mutational subclass: wt""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03495481""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1001734""","""NONE""",,"""GSM1662778""",
"""GSM1817093""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-11""","""Homo sapiens""","""patient id: Breast-H11""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: PIK3CA""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854086""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091597""","""NONE""",,"""GSM1817093""",
"""GSM1817094""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H31-TR-489""","""Homo sapiens""","""patient id: Breast-H31""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854087""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091598""","""NONE""",,"""GSM1817094""",
"""GSM1817095""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H38-TR467""","""Homo sapiens""","""patient id: Breast-H38""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854088""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091599""","""NONE""",,"""GSM1817095""",
"""GSM1817096""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-59""","""Homo sapiens""","""patient id: Breast-H59""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854089""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091600""","""NONE""",,"""GSM1817096""",
"""GSM1817097""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H63-TR-491""","""Homo sapiens""","""patient id: Breast-H63""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854090""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091601""","""NONE""",,"""GSM1817097""",
"""GSM1817098""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-66""","""Homo sapiens""","""patient id: Breast-H66""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854091""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091602""","""NONE""",,"""GSM1817098""",
"""GSM1817099""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-68""","""Homo sapiens""","""patient id: Breast-H68""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854092""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091603""","""NONE""",,"""GSM1817099""",
"""GSM1817100""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-74""","""Homo sapiens""","""patient id: Breast-H74""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854093""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091604""","""NONE""",,"""GSM1817100""",
"""GSM1817101""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H-75""","""Homo sapiens""","""patient id: Breast-H75""","""cancer type: Breast""","""batch: Batch05""","""mutational subclass: PIK3CA""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854094""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091605""","""NONE""",,"""GSM1817101""",
"""GSM1817102""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H76-TR469""","""Homo sapiens""","""patient id: Breast-H76""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854095""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091606""","""NONE""",,"""GSM1817102""",
"""GSM1817103""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H81-TR492""","""Homo sapiens""","""patient id: Breast-H81""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854096""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091607""","""NONE""",,"""GSM1817103""",
"""GSM1817104""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H83-TR550""","""Homo sapiens""","""patient id: Breast-H83""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854097""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091608""","""NONE""",,"""GSM1817104""",
"""GSM1817105""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H84-TR551""","""Homo sapiens""","""patient id: Breast-H84""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854098""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091609""","""NONE""",,"""GSM1817105""",
"""GSM1817106""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H89-TR471""","""Homo sapiens""","""patient id: Breast-H89""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854099""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091610""","""NONE""",,"""GSM1817106""",
"""GSM1817107""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-BrCa-H92-TR472""","""Homo sapiens""","""patient id: Breast-H92""","""cancer type: Breast""","""batch: Batch06""","""mutational subclass: HER2+""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854100""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091611""","""NONE""",,"""GSM1817107""",
"""GSM1817108""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-CRC-BRAF4-TR547""","""Homo sapiens""","""patient id: Chol-BRAF4""","""cancer type: Hepatobiliary""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854101""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091612""","""NONE""",,"""GSM1817108""",
"""GSM1817109""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-CRC-368""","""Homo sapiens""","""patient id: CRC-368""","""cancer type: CRC""","""batch: Batch05""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854102""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091613""","""NONE""",,"""GSM1817109""",
"""GSM1817110""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-CRC-412-TR466""","""Homo sapiens""","""patient id: CRC-412""","""cancer type: CRC""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854103""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091614""","""NONE""",,"""GSM1817110""",
"""GSM1817111""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-CRC-BRAF5-TR548""","""Homo sapiens""","""patient id: CRC-BRAF5""","""cancer type: CRC""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854104""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091615""","""NONE""",,"""GSM1817111""",
"""GSM1817112""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-CRC-BRAF6-TR465""","""Homo sapiens""","""patient id: CRC-BRAF6""","""cancer type: CRC""","""batch: Batch06""","""mutational subclass: wt""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854105""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091616""","""NONE""",,"""GSM1817112""",
"""GSM1817113""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""Vumc-NSCLC-49""","""Homo sapiens""","""patient id: Lung-49""","""cancer type: Lung""","""batch: Batch05""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854106""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091617""","""NONE""",,"""GSM1817113""",
"""GSM1817114""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""Vumc-NSCLC-57""","""Homo sapiens""","""patient id: Lung-57""","""cancer type: Lung""","""batch: Batch05""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854108""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091618""","""NONE""",,"""GSM1817114""",
"""GSM1817115""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""Vumc-NSCLC-59""","""Homo sapiens""","""patient id: Lung-59""","""cancer type: Lung""","""batch: Batch05""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854109""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091619""","""NONE""",,"""GSM1817115""",
"""GSM1817116""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L01-TR458""","""Homo sapiens""","""patient id: Lung-L01""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854070""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091620""","""NONE""",,"""GSM1817116""",
"""GSM1817117""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L03-TR488""","""Homo sapiens""","""patient id: Lung-L03""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854071""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091621""","""NONE""",,"""GSM1817117""",
"""GSM1817118""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L07-TR459""","""Homo sapiens""","""patient id: Lung-L07""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854072""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091622""","""NONE""",,"""GSM1817118""",
"""GSM1817119""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L11-TR477""","""Homo sapiens""","""patient id: Lung-L11""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854073""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091623""","""NONE""",,"""GSM1817119""",
"""GSM1817120""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L12-TR478""","""Homo sapiens""","""patient id: Lung-L12""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854074""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091624""","""NONE""",,"""GSM1817120""",
"""GSM1817121""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L18-TR479""","""Homo sapiens""","""patient id: Lung-L18""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854075""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091625""","""NONE""",,"""GSM1817121""",
"""GSM1817122""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L19-TR461""","""Homo sapiens""","""patient id: Lung-L19""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854076""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091626""","""NONE""",,"""GSM1817122""",
"""GSM1817123""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L20-TR500""","""Homo sapiens""","""patient id: Lung-L20""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854107""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091627""","""NONE""",,"""GSM1817123""",
"""GSM1817124""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L22-TR462""","""Homo sapiens""","""patient id: Lung-L22""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854077""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091628""","""NONE""",,"""GSM1817124""",
"""GSM1817125""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L23-TR524""","""Homo sapiens""","""patient id: Lung-L23""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854078""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091629""","""NONE""",,"""GSM1817125""",
"""GSM1817126""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L25-TR480""","""Homo sapiens""","""patient id: Lung-L25""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854079""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091630""","""NONE""",,"""GSM1817126""",
"""GSM1817127""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L39-TR519""","""Homo sapiens""","""patient id: Lung-L39""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854080""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091631""","""NONE""",,"""GSM1817127""",
"""GSM1817128""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L40-TR520""","""Homo sapiens""","""patient id: Lung-L40""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854081""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091632""","""NONE""",,"""GSM1817128""",
"""GSM1817129""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L51-TR521""","""Homo sapiens""","""patient id: Lung-L51""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854082""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091633""","""NONE""",,"""GSM1817129""",
"""GSM1817130""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L58-TR525""","""Homo sapiens""","""patient id: Lung-L58""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: EGFR""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854083""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091634""","""NONE""",,"""GSM1817130""",
"""GSM1817131""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L59-TR522""","""Homo sapiens""","""patient id: Lung-L59""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854084""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091635""","""NONE""",,"""GSM1817131""",
"""GSM1817132""","""Public on Oct 30 2015""","""Jul 10 2015""","""May 15 2019""","""SRA""","""1""","""MGH-NSCLC-L65-TR523""","""Homo sapiens""","""patient id: Lung-L65""","""cancer type: Lung""","""batch: Batch06""","""mutational subclass: KRAS""","""tissue: blood""","""cell type: thrombocytes""","""total RNA""","""Blood platelets were isolated from whole blood in purple-cap BD Vacutainers containing the EDTA anti-coagulant. The cells and aggregates were removed by centrifugation at room temperature for 20 minutes at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 minutes at 360g. The platelet pellet was collected in 30 μl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers’ protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 μl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using Bioanalyzer 2100 with RNA 6000 Picochip (Agilent).""","""100-500 pg of platelet total RNA (Bioanalyzer RIN values >7 and/or distinctive rRNA curves) diluted in nuclease free H2O was subjected to cDNA synthesis and amplification using the SMARTer Ultra Low RNA Kit for Illumina Sequencing v1 (Clontech, cat. nr. 634936) according to the manufacturers’ protocol. Conversion and efficient amplification of cDNA was quality-controlled using the Bioanalyzer 2100 with DNA High Sensitivity chip (Agilent). Samples with detectable fragments in the 300-7500 bp region were selected for further processing and Covaris shearing by sonication (Covaris Inc). Sample preparation for Illumina sequencing was performed using the Truseq DNA Sample Preparation Kit (Illumina, cat nr. FC-121-2001) or Truseq Nano DNA Sample Preparation Kit (Illumina, cat nr. FC-121-4001). Sample quality and quantity was measured using the DNA 7500 chip or DNA High Sensitivity chip (Agilent). High-quality samples with product sizes between 300-500 bp were pooled in equimolar concentrations (8-12 samples per Hiseq lane) and submitted for 100 bp Single Read sequencing on the Hiseq 2500 platform (Illumina).""","""9606""","""""","""Single-end 100 bp reads were subjected to pre-aligment 5'-end quality trimming and sequence adapter clipping using Trimmomatic.""","""Cleaned-up reads were mapped to the hg19 reference genome using STAR (version 2.3.0), using splice aware alignments and allowing for 10 mismatches.""","""Selection of intron-spanning reads was performed using Picard-tools (version 1.115)""","""Read summarization was performed using HTSeq (version 0.6.1) using union-mode, unstranded reads and minimal mapping quality of 35, all guided by the Ensembl gene annotation version 75.""","""Genome_build: hg19""","""Supplementary_files_format_and_content: Samples in the tab-delimited text file were processed according to the described protocol and data of all samples was merged in a comprehensive read count matrix.""","""GPL16791""","""Myron,,Best""","""m.best@vumc.nl""","""Neuro-oncology Research Group""","""Neurosurgery""","""VU University Medical Center""","""De Boelelaan 1117""","""Amsterdam""","""1081 HV""","""Netherlands""","""0""","""Illumina HiSeq 2500""","""cDNA""","""transcriptomic""","""RNA-Seq""","""BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN03854085""","""SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1091636""","""NONE""",,"""GSM1817132""",
